Brian R Leyland-Jones
Overview
Explore the profile of Brian R Leyland-Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun Y, Lin X, Aske J, Ye P, Williams C, Abramovitz M, et al.
Cancer Chemother Pharmacol
. 2019 Sep;
84(6):1241-1256.
PMID: 31541266
Purpose: Triple-negative breast cancer (TNBC) has a poor prognosis because of limited treatment options. The combination of a poly ADP ribose polymerase (PARP) inhibitor with a DNA-damaging agent has shown...
2.
Willis S, De P, Dey N, Long B, Young B, Sparano J, et al.
Meta Gene
. 2015 May;
4:129-41.
PMID: 26005638
Purpose: Triple negative (TN) breast cancers which lack expression of the estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors convey a poor prognosis due in part...
3.
De P, Sun Y, Carlson J, Friedman L, Leyland-Jones B, Dey N
Neoplasia
. 2014 Feb;
16(1):43-72.
PMID: 24563619
Phosphoinositide 3-kinase (PI3K) pathway, in addition to its pro-proliferative and antiapoptotic effects on tumor cells, contributes to DNA damage repair (DDR). We hypothesized that GDC-0980, a dual PI3K-mammalian target of...
4.
Dey N, Barwick B, Moreno C, Ordanic-Kodani M, Chen Z, Oprea-Ilies G, et al.
BMC Cancer
. 2013 Nov;
13:537.
PMID: 24209998
Background: Triple Negative subset of (TN) Breast Cancers (BC), a close associate of the basal-like subtype (with limited discordance) is an aggressive form of the disease which convey unpredictable, and...
5.
Long Q, Johnson B, Osunkoya A, Lai Y, Zhou W, Abramovitz M, et al.
Am J Pathol
. 2011 Jun;
179(1):46-54.
PMID: 21703393
An important challenge in prostate cancer research is to develop effective predictors of tumor recurrence following surgery to determine whether immediate adjuvant therapy is warranted. To identify biomarkers predictive of...
6.
Loi S, Fraser Symmans W, Bartlett J, Fumagalli D, Veer L, Forbes J, et al.
Lancet Oncol
. 2011 Jun;
12(12):1162-8.
PMID: 21684810
In this Personal View, we outline proposals for uniform collection of biospecimens obtained in neoadjuvant breast cancer trials undertaken by the Breast International Group (BIG) and the National Cancer Institute-sponsored...
7.
Tang W, David F, Wilson M, Barwick B, Leyland-Jones B, Bouzyk M
Cold Spring Harb Protoc
. 2010 Feb;
2009(2):pdb.prot5138.
PMID: 20147068
No abstract available.
8.
Leyland-Jones B, Ambrosone C, Bartlett J, Ellis M, Enos R, Raji A, et al.
J Clin Oncol
. 2008 Oct;
26(34):5638-44.
PMID: 18955459
Recommendations for specimen collection and handling have been developed for adoption across breast cancer clinical trials conducted by the Breast International Group (BIG)-sponsored Groups and the National Cancer Institute (NCI)-sponsored...